vorinostat has been researched along with Adrenal Cortex Cancer in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Demeure, MJ | 1 |
| Coan, KE | 1 |
| Grant, CS | 1 |
| Komorowski, RA | 1 |
| Stephan, E | 1 |
| Sinari, S | 1 |
| Mount, D | 1 |
| Bussey, KJ | 1 |
1 other study available for vorinostat and Adrenal Cortex Cancer
| Article | Year |
|---|---|
PTTG1 overexpression in adrenocortical cancer is associated with poor survival and represents a potential therapeutic target.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents; Biomarkers, | 2013 |